Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma

被引：0

作者：

Dummer, Reinhard

Robert, Caroline

Nyakas, Marta

McArthur, Grant A.

Kudchadkar, Ragini Reiney

Gomez-Roca, Carlos

Sullivan, Ryan J.

Flaherty, Keith

Murer, Carla

Michel, Daniela

Tang, Zhongwen

De Parseval, Laure A.

Delord, Jean-Pierre

机构：

[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland

[2] Inst Gustave Roussy, Villejuif, France

[3] Oslo Univ Hosp, Oslo, Norway

[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[6] Inst Claudius Regaud, Toulouse, France

[7] Massachusetts Gen Hosp, Boston, MA 02114 USA

[8] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Pharmaceut, E Hanover, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9028

引用

页数：1

共 50 条

[41] A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors
Kieran, Mark W.
Geoerger, Birgit
Dunkel, Ira J.
Broniscer, Alberto
Hargrave, Darren
Hingorani, Pooja
Aerts, Isabelle
Bertozzi, Anne-Isabelle
Cohen, Kenneth J.
Hummel, Trent R.
Shen, Violet
Bouffet, Eric
Pratilas, Christine A.
Pearson, Andrew D. J.
Tseng, Lillian
Nebot, Noelia
Green, Steven
Russo, Mark W.
Whitlock, James A.
CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7294 - 7302
[42] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
Minami, Hironobu
Ando, Yuichi
Ma, Brigette Buig Yue
Lee, Jih-Hsiang
Momota, Hiroyuki
Fujiwara, Yutaka
Li, Leung
Fukino, Koichi
Ito, Koji
Tajima, Takeshi
Mori, Asuka
Lin, Chia-Chi
CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
[43] LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma
Dummer, R.
Sandhu, S.
Hassel, J. C.
Munoz, E.
Berking, C.
Gesierich, A.
Ascierto, P. A.
Esposito, O.
Carter, K.
Antona, V.
Radhakrishnan, R.
Cui, X.
Caponigro, G.
Jaeger, S.
Demuth, T.
Miller, W. H., Jr.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S667 - S668
[44] Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM)
Daud, Adil
Weber, Jeffrey S.
Sosman, Jeffrey Alan
Kim, Kevin
Gonzalez, Rene
Hamid, Omid
Infante, Jeffrey R.
Cebon, Jonathan S.
Schuchter, Lynn Mara
Long, Georgina V.
Algazi, Alain Patrick
Kudchadkar, Ragini Reiney
Puzanov, Igor
Lawrence, Donald P.
Kefford, Richard
Kline, Amy S.
Del Buono, Heather Lynn
Sun, Peng
McDowell, Diane Opatt
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[45] A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D plus T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)
Gonzalez, M.
Menzies, A. M.
Saw, R.
Thompson, J. F.
Spillane, A. J.
Howle, J.
Nieweg, O.
Shannon, K.
Ch'Ng, S.
Stretch, J. F.
Carlino, M. S.
Guminski, A.
Emmett, L.
Rizos, H.
Scolyer, R. A.
Long, G. V.
ANNALS OF ONCOLOGY, 2017, 28
[46] COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
di Pietro, Alessandra
Cantey-Kiser, Jean
Edwards, Michelle
Ascierto, Paolo A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4178 - +
[47] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
Papadopoulos, K. P.
Mendelson, D. S.
Tolcher, A. W.
Patnaik, A.
Burris, H. A.
Rasco, D. W.
Bendell, J. C.
Gordon, M. S.
Kato, G.
Wong, H.
Bomba, D.
Lee, S.
Gillenwater, H. H.
Woo, T.
Infante, J. R.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[48] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
Song, Yan
Wang, Jinwan
Ren, Xiubao
Jin, Jie
Mao, Li
Liang, Chris
Ding, Lieming
Yang, Lin
CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (01) : 103 - +
[49] FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial
Nti, Akosua A.
Serrano, Leona W.
Sandhu, Harpal S.
Uyhazi, Katherine E.
Edelstein, Ilaina D.
Zhou, Elaine J.
Bowman, Scott
Song, Delu
Gangadhar, Tara C.
Schuchter, Lynn M.
Mitnick, Sheryl
Huang, Alexander
Nichols, Charles W.
Amaravadi, Ravi K.
Kim, Benjamin J.
Aleman, Tomas S.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (03): : 502 - 513
[50] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
Michael S. Gordon
David S. Mendelson
Mitchell Gross
Martina Uttenreuther-Fischer
Mahmoud Ould-Kaci
Yihua Zhao
Peter Stopfer
David B. Agus
Investigational New Drugs, 2013, 31 : 409 - 416

← 1 2 3 4 5 →